Ultragenyx Pharmaceutical Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on June 18, 2020. The report discloses a significant regulatory milestone and a related investor presentation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a regulatory event rather than periodic financial results.
Material Changes and Events
- Regulatory Approval: The U.S. Food and Drug Administration (FDA) approved Crysvita (burosumab) for the treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia (TIO).
- Indication Details: The approval covers adults and pediatric patients 2 years of age and older with TIO associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized.
- Collaboration: The approval was announced via a joint press release with Kyowa Kirin Co., Ltd.
Guidance, Outlook, and Risks
The filing references a presentation posted to the company's website on June 18, 2020, under the "Investors" tab. The text explicitly states that the information in the presentation is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. No specific financial guidance, risk factors, or contingencies are detailed within the body of this 8-K text.
Key Facts for Investor Verification
- Verify the commercial launch timeline and sales expectations for Crysvita in the new TIO indication.
- Review the full joint press release (Exhibit 99.1) for details on the commercial partnership with Kyowa Kirin.
- Access the investor presentation referenced in Item 7.01 for potential updates on the company's pipeline and financial outlook.
- Confirm the specific patient population size and market potential for the newly approved indication.